Esketamine Nasal Spray Beneficial for Treatment-Resistant Depression

THURSDAY, Oct. 5, 2023 (HealthDay News) -- For patients with treatment-resistant depression, esketamine nasal spray is superior to extended-release quetiapine with respect to remission at week 8, according to a

Related Keywords

Germany ,Frankfurt ,Brandenburg ,Andreas Reif ,Goethe University Hospital In Frankfurt ,Healthday News ,New England Journal ,Goethe University Hospital ,Depression Rating Scale ,Physicians Briefing ,